Last Updated on October 2, 2024 by The Health Master
USFDA approval
Gland Pharma, a leading manufacturer of generic injectable drugs, has achieved a significant breakthrough with the U.S. Food and Drug Administration approval (USFDA approval) for its Eribulin Mesylate Injection (0.5 mg/mL Single Dose Vial).
This marks a major development in the fight against breast cancer, offering patients a potentially more affordable treatment option.
First-Mover Advantage in a Billion-Dollar Market
Eribulin Mesylate Injection is a critical medication used to treat metastatic breast cancer, a later stage where cancer cells have spread beyond the original tumor.
The drug also holds promise in treating liposarcoma, a type of soft tissue cancer.
According to industry data provider IQVIA, the branded Eribulin Mesylate generated approximately $92 million in sales within the U.S. for the twelve months ending February 2024.
Gland Pharma’s USFDA approval positions them to become the first generic provider in this market, offering substantial cost savings for patients and healthcare systems.
Strategic Partnership Ensures Swift Launch
Gland Pharma strategically collaborated with Orbicular Pharmaceutical Technologies Private Limited for the co-development of Eribulin Mesylate Injection.
This partnership combines Gland Pharma’s expertise in generic injectable manufacturing with Orbicular’s proficiency in complex drug development.
The company expects a swift launch of the generic Eribulin Mesylate Injection in the near future through its established marketing partner network.
This will significantly improve patient access to this vital breast cancer treatment.
A Bright Future for Affordable Cancer Care
Gland Pharma’s USFDA approval for Eribulin Mesylate Injection represents a significant advancement in the realm of affordable cancer treatment. This generic version has the potential to:
- Reduce healthcare costs associated with breast cancer treatment.
- Increase patient access to this life-saving medication.
- Drive innovation within the generic injectable drug market.
Gland Pharma‘s achievement is a testament to their commitment to developing high-quality, affordable generic medications for critical illnesses.
This USFDA approval paves the way for a future where effective cancer treatment becomes more accessible to patients worldwide.
Disclaimer: This article contains information derived from the source mentioned below. Our team utilized an AI language model to rewrite and present the news or article in a unique format.
USFDA approval granted for Migalastat Capsules
USFDA approval granted for Eslicarbazepine Acetate Tablets
USFDA approval granted for Mometasone Furoate Monohydrate Nasal Spray
USFDA Approval granted for Aripiprazole Tablets: Lupin
USFDA approval granted for generic Doxycycline for Injection
CDSCO Seeks More Medical Device Testing Laboratory Registrations
USFDA issues Warning Letter to Natco Pharma for Telangana Plant
USFDA completes inspection at Aurobindo with 3 observations
CDSCO Approval granted for Early Cancer Detection Test
DTAB: Pain Relief Combo Faces New Ban Recommendation
Chemists Association approaches Govt on Discount Pharmacies: Kerala
DCA Telangana Cracks Down on Drug Manufacturing License Forgery
Compounding Of Offence Under Jan Vishwas Act
For informative videos by The Health Master, click on the below YouTube icon:
For informative videos on Medical Store / Pharmacy, click on the below YouTube icon:
For informative videos on the news regarding Pharma / Medical Devices / Cosmetics / Homoeopathy etc., click on the below YouTube icon:
For informative videos on consumer awareness, click on the below YouTube icon:
